Alnylam Commemorates 10th Anniversary of the Nobel Prize in Physiology or Medicine Awarded for the Discovery of RNAi

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. IBM
10. HOOD

Go back to Alnylam Commemorates 10th Anniversary of the Nobel Prize in Physiology or Medicine Awarded for the Discovery of RNAi

Alnylam Pharma (ALNY) to Discontinue Development of Revusiran; Decision Will Not Affect Patisiran

October 5, 2016 4:31 PM EDT

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the Company has decided to discontinue development of revusiran, an investigational RNA interference (RNAi) therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). This... More